The latest price target for Regeneron Pharmaceuticals (NASDAQ:REGN) was reported by Morgan Stanley on July 8, 2026. The analyst firm set a price target for $730.00 expecting REGN to rise to within 12 months (a possible 10.13% upside). 69 analyst firms have reported ratings in the last year.

The latest analyst rating for Regeneron Pharmaceuticals (NASDAQ:REGN) was provided by Morgan Stanley, and Regeneron Pharmaceuticals maintained their equal-weight rating.

The last upgrade for Regeneron Pharmaceuticals Inc happened on July 7, 2026 when Benchmark raised their price target to $185. Benchmark previously had a hold for Regeneron Pharmaceuticals Inc.

The last downgrade for Regeneron Pharmaceuticals Inc happened on May 18, 2026 when Citigroup changed their price target from $900 to $700 for Regeneron Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regeneron Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regeneron Pharmaceuticals was filed on July 8, 2026 so you should expect the next rating to be made available sometime around July 8, 2027.

While ratings are subjective and will change, the latest Regeneron Pharmaceuticals (REGN) rating was a maintained with a price target of $788.00 to $730.00. The current price Regeneron Pharmaceuticals (REGN) is trading at is $662.88, which is out of the analyst’s predicted range.